Go to deals
Healthcare | Private Equity

E-Swin has been acquired by M Capital Groupe and Ciclad

The owner of E-Swin has sold the company to M Capital Groupe and Ciclad, two French tier one private equity funds. Financial details have not been disclosed.

E-Swin manufactures laser hair removal devices for men and women. It also offers optic cartridges, optical gels, pencils and sharpeners, safety glasses, patches, guide plates, stencils, optical sprays and Ebags. The company offers its products online. E-Swin was founded in 2007 and is based in Adainville, France.

M Capital Groupe is a French equity firm specialized in capital investment and real estate development. Ciclad is a private equity firm investing from US$5-18 million in companies valued between US$6-60 million in all economic sectors both in France and abroad.

Oaklins' team in France advised the seller in this transaction.

Parties

Talk to the deal team

Hadrien Mollard

Managing Partner
Paris, France
Oaklins France

Related deals

Afric Phar has been acquired by Pharma Capital
Healthcare

Afric Phar has been acquired by Pharma Capital

Pharma Capital S.A. has acquired a significant stake in the Moroccan pharmaceutical group Afric Phar, which includes leading companies Afric Phar, Pharmis and Partner Lab, from the Chaoui family, in one of the largest transactions in the Moroccan pharmaceutical sector.

Learn more
Den Berk Délice accelerates growth through strategic partnership
Private Equity | Agriculture

Den Berk Délice accelerates growth through strategic partnership

Den Berk Délice, a leading Belgian grower of specialty tomatoes, has entered a strategic partnership with Egeria, an independent investment firm, to realize its next growth phase.

Learn more
Xiel Limited has been acquired by MIS Healthcare
Private Equity | Healthcare

Xiel Limited has been acquired by MIS Healthcare

MIS Healthcare, a leading distributor in medical imaging, has successfully acquired Xiel Limited. This strategic acquisition merges MIS Healthcare’s extensive radiotherapy portfolio with Xiel’s specialized expertise in nuclear medicine, radiotherapy and diagnostic radiology. The merger strengthens both companies’ positions in the rapidly growing fields of oncology and nuclear medicine, promising to deliver exceptional value to the healthcare community in the UK and Ireland.

Learn more